Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PLTR earned a consensus upgrade this week. The average analyst target now stands at $200.88, up from $199.84. That move reflects growing Wall Street confidence in the AI data firm.
VLO saw the biggest target price jump in the latest batch of changes. Analysts lifted the average target to $387.05 from $380.00. That is an almost 2% increase in the price goal for the refiner.
Pharma names drew attention too. ABBV targets edged up to $280.96, while ORTEX alt data shows trial completion date slippage at AbbVie running 2.1 standard deviations below its own history. That could suggest faster-than-usual trial progress, adding context to the mild target lift.
REGN and both saw small positive target revisions. Regeneron's consensus target reached $859.04.
On the downside, MCD targets slipped to $292.21 from $293.76. PCAR also saw a modest cut, with the average target falling to $140.06 from $141.44.
PYPL and FIS both absorbed small target reductions. Neither saw a rating change, but the direction of travel is negative.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
